Skip to content

Predicting Treatment Resistance in Schizophrenia

Predicting Treatment Resistance in Schizophrenia - TREVOS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON48828
Enrollment
120
Registered
2018-04-18
Start date
2018-05-29
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

first episode psychosis schizophrenia

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: For patients: - First episode psychosis - Age 18-35 years old;For healthy contols: - Age 18-35 years old

Exclusion criteria

Exclusion criteria: - Antipsychotic use longer than one year - Dependence on other substances of abuse than nicotine or cannabis - Use of amphetamine, cocaine or medication for ADHD (attention deficit hyperactivity disorder), since these drugs influence the dopamine system - Neurological disorder (e.g. epilepsy) or evidence of brain damage - Inability to provide informed consent;In addition to the exclusion criteria mentioned above, healthy control subjects are not allowed to have any kind of psychiatric disorder;Exclusion criteria directly related to MRI scanning: - Contra-indications for MRI (including pacemaker, ferromagnetic implants, claustrophobia) - Pregnancy;Exclusion criteria directly related to PET/CT scanning (for subgroup of 40 patients): - Participation in a scientific examination where radiation was used, in the last year. - Positive urine drug screen on the day of the PET/CT scan. Participants will be tested on cannabis, amphetamine, XTC, cocaine and opiates. Only recent cannabis use will be accepted. - In women: positive pregnancy test on the day of the PET/CT scan and lactation.

Design outcomes

Primary

MeasureTime frame
- Treatment resistance - Neuromelanin contrast ratio on nMRI - Glutamate/Creatine ratio on MRS in ACC - Plasma DDC activity - [18F]DOPA influx (Ki) value (for subgroup of 40 patients)

Secondary

MeasureTime frame
- Side effects of antipsychotics - Symptom scores on PANSS - Neuropsychological ratings

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)